Pharmaceutical News

RSS

Nordic Naturals' dietary supplements earn NSF certification

Nordic Naturals has earned certification from NSF International, verifying that its new LEED-designed corporate headquarters complies with Good Manufacturing Practices as set forth in NSF/ANSI Standard 173-2008, Dietary Supplements, Section 8.

17 May 2011

Antiretrovirals important to protect HIV-positive children from measles

Scientific American looks at the possible link between HIV prevalence and a recent increase in the number of children dying from measles in sub-Saharan Africa. "Studies show that infants with HIV do not respond well to the measles vaccine even when given a second dose at nine months, as the World Health Organization currently recommends," the article notes.

17 May 2011

World Health Assembly begins in Geneva

As the 64th World Health Assembly gets underway in Geneva, the body will consider "an array of subjects pertaining to reforms of the organisation and its financing, vaccines, fake medicines, and influenza pandemic preparedness, as well as communicable and non-communicable diseases," Intellectual Property Watch reports.

17 May 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

Epichem signs exclusive distributor agreement with AR Brown

Australian supplier of API analytical standards Epichem, announced today it has signed an exclusive distributor agreement with a leading Japanese Life Sciences supplier company, AR Brown, for sales to Japan, Taiwan, China and South Korea.

17 May 2011

Benitec raises AU$8 million for gene silencing therapeutics

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced its fully underwritten AU$8 million renounceable rights issue, incorporating an entitlement offer and a shortfall offer, had successfully closed oversubscribed.

17 May 2011

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such resistance, but first they must understand why and how it happens.

17 May 2011

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.

17 May 2011

Perrigo's ANDA for generic Zantac 150 receives FDA final approval to treat heartburn

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Ranitidine 150, a generic version of Zantac 150.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Opinion: New HIV infections more expensive than providing antiretroviral drugs to existing patients

In light of study findings released last week showing the risk of HIV transmission can be reduced by 96 percent if HIV-positive patients begin combination antiretroviral therapy as soon as possible, a San Francisco Chronicle editorial asks, "The evidence is clearly starting to show that it's much better to treat patients earlier, but from where will the money come?".

17 May 2011

FDA warns consumers about look like antimicrobial dietary supplements

The FDA is warning consumers not to use products marketed as dietary supplements that also claim to be antimicrobial (antibiotic, antifungal or antiviral) drugs. These illegal products are falsely promoted with claims to treat illnesses such as upper respiratory infections, sinusitis, pneumonia, bronchitis and the common cold.

16 May 2011

Mylan introduces Bromfenac Ophthalmic Solution for cataract postoperative inflammation treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bromfenac Ophthalmic Solution, 0.09%, based on a development and supply agreement with Coastal Pharmaceuticals.

16 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

Study finds no potential cardiovascular risks of ADHD medications in children, adolescents

Despite recent concerns that medications for attention deficit hyperactivity disorder could increase the risk of cardiovascular events in children and adolescents, an observational study conducted by researchers at the University of Pennsylvania School of Medicine and HealthCore Inc. finds they are no more likely to die from a severe cardiovascular event than those who do not take the drugs.

16 May 2011

Study: HIV treatment drugs slash transmission risk

AIDS researchers offered evidence backing up the long-standing idea that people infected with HIV who are being treated are much less likely to transmit the virus than those who are not on drugs. This finding is being hailed as a breakthrough.

16 May 2011

Counterfeit medicines posing increasing risk to patients worldwide, U.N. agency says

Counterfeit medications are posing an increasing threat to patients' health worldwide, because they offer high returns and low risks for criminal organizations, the U.N. Office on Drugs and Crime said in a statement on Friday, Agence France-Presse reports.

16 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011

Pharmaceutical News

Nordic Naturals' dietary supplements earn NSF certification

Antiretrovirals important to protect HIV-positive children from measles

World Health Assembly begins in Geneva

Novel topically-applied molecular microbicide protects women against HIV infection

Eli Lilly responds to Amylin's exenatide lawsuit

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Epichem signs exclusive distributor agreement with AR Brown

Benitec raises AU$8 million for gene silencing therapeutics

Abcc10 might help counter resistance and extend effectiveness of anticancer drugs

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

Perrigo's ANDA for generic Zantac 150 receives FDA final approval to treat heartburn

FDA nod for hepatitis C drug

Opinion: New HIV infections more expensive than providing antiretroviral drugs to existing patients

FDA warns consumers about look like antimicrobial dietary supplements

Mylan introduces Bromfenac Ophthalmic Solution for cataract postoperative inflammation treatment

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Study finds no potential cardiovascular risks of ADHD medications in children, adolescents

Study: HIV treatment drugs slash transmission risk

Counterfeit medicines posing increasing risk to patients worldwide, U.N. agency says

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News